University of Dundee, MSc Human Clinical Embryology and Assisted Conception - Apply now for September 2018
Page URL: https://www.bionews.org.uk/page_92895

Stem cell research may help treat common blindness

28 March 2011
Appeared in BioNews 601

US scientists have taken an important step towards using stem cells to treat age-related macular degeneration (AMD), the leading cause of blindness in the UK. The study demonstrates, for the first time, the ability to direct human iPS cells (induced pluripotent stem cells) to become the type of eye cells that die and cause loss of sight in sufferers of the disease.

'We have shown that we are able to generate retinal cells from cells originally taken from a small amount of biopsied skin, that are then induced to become stem cells', explained study leader Dr Nady Golestaneh from Georgetown University Medical Centre in Washington, DC. 'The retinal cells we have generated are really functional… they mimic the function of native retinal cells that play a key role in the eye for light absorption, nutrition and receptor function'.

AMD affects a small part of the retina at the back of the eye, leading to death of retinal pigment epithelial (RPE) cells, a coloured layer which nourishes the light-receiving cells of the retina. Around one in 50 people more than 50 years of age, and up to one in five people over the age of 85, are affected by the disease, which results in the gradual loss of central vision needed for daily tasks such as reading and driving.

While existing treatments slow the progression of AMD, there is currently no cure. Human iPS cells offer the potential to use patient-specific stem cells to generate retinal cells for transplant. However, for transplantation to be possible, the iPS cells must first be programmed to possess the characteristics of native RPE cells and, until now, there has not been evidence that iPS-derived RPE cells have the required ability.

The study authors were careful to stress that their work is preliminary and much future research is needed before these cells can be used clinically. They pointed out that the cells they produced also displayed some structural abnormalities and chromosome damage, highlighting the need to focus on generating 'safe', as well as viable, iPS-derived cells.

'We also identified some issues that need to be worked out before these cells are ready for transplantation but overall, this is a tremendous step forward in regenerative medicine', concluded Dr Golestaneh. The study was published in the journal Stem Cells. 

SOURCES & REFERENCES
Human iPS-Derived Retinal Pigment Epithelium (RPE) Cells Exhibit Ion Transport, Membrane Potential, Polarized VEGF Secretion and Gene Expression Pattern Similar to Native RPE
Stem Cells |  24 March 2011
Progress seen in creating eye cells from stem cells
WFMJ |  24 March 2011
Stem cell therapy for age-related macular degeneration - a step closer to reality
Physorg.com |  24 March 2011
Stem cell therapy for age-related macular degeneration - a step closer to reality
EurekAlert (press release) |  24 March 2011
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
3 December 2012 - by Dr Greg Ball 
Induced pluripotent stem (iPS) cells have been created from a routine blood sample by researchers at the University of Cambridge in the UK, marking an improvement over existing experimental methods that require more invasive tissue biopsies....
31 January 2012 - by Rosemary Paxman 
A clinical trial testing the safety of using human embryonic stem cell (hESC) in the treatment of progressive eye conditions has been carried out by researchers in the USA...
31 January 2012 - by Dr Dusko Ilic and Dr Emma Stephenson 
Last week, Advanced Cell Technology (ACT) of Massachusetts, USA, made two important announcements regarding human embryonic stem (hES) cell-based therapies for the potential treatment of Stargardt's dystrophy and age-related macular degeneration, two devastating degenerative disease leading to blindness....
26 September 2011 - by Dr Rachael Panizzo 
UK scientists have been granted approval to begin the first clinical trial using embryonic stem cells (ES cells) in Europe, which they hope could lead to an effective treatment for a degenerative eye disease causing blindness...
18 July 2011 - by Dr Sophie Pryor 
Doctors in the USA have begun treating patients in two clinical trials for degenerative eye diseases. The studies at the Jules Stein Eye Institute at the University of California, Los Angeles (UCLA), will test whether specialised eye cells, which have been produced from human embryonic stem cells (hESCs), can be used to treat dry age-related macular degeneration (dry AMD) and Stargardt's macular dystrophy....
20 June 2011 - by Dr Rebecca Robey 
Two clinical trials to test whether embryonic stem cells can treat two incurable eye disorders have been launched in the USA. Twenty-four patients will be treated during the trials at the Jules Stein Eye Institute at the University of California, Los Angeles (UCLA)...
11 April 2011 - by Dr Rachael Panizzo 
Embryonic stem cells have been used to generate a basic retina, the part of the eye that detects light and is needed for vision. The retinal tissue could be used to treat some forms of blindness, such as retinitis pigmentosa and age-related macular degeneration, and to investigate and screen potential new drugs for a range of eye diseases....
14 December 2009 - by Dr Marianne Kennedy 
New research offers promise of restoring vision in patients with congenital or acquired corneal scarring. The findings were presented at the 49th Annual Meeting of the American Society of Cell Biology in San Diego, US....
1 November 2009 - by Dr Marianne Kennedy 
US doctors have used gene therapy to restore significant vision in 12 patients who were previously blinded by a disease called Leber's congenital amaurosis. The study, conducted by researchers at the Children`s Hospital of Philadelphia and the University of Pennsylvania School of Medicine, was published online in the Lancet on 24 October....
20 April 2009 - by Ailsa Stevens 
Clinicians from the Institute of Ophthalmology at University College London and Moorfields eye hospital have predicted that an experimental new therapy for treating Age-related Macular Degeneration (AMD), the leading cause of blindness in the developed world, may become routinely available within the next six to seven years...
25 September 2006 - by Heidi Nicholl 
Scientists from Advanced Cell Technology (ACT) working in collaboration with eye specialists from the University of Utah, have used human embryonic stem (ES) cells to partly restore vision in rats suffering from a form of degenerative blindness used to mimic macular degeneration. According to Robert Lanza of...
14 August 2005 - by BioNews 
US scientists have used gene therapy to successfully treat mice with a rare genetic disorder that causes blindness, called retinoschisis. The researchers, based at the University of Florida Genetics Institute, say their method could eventually be used to treat a range of eye diseases in humans. Retinoschisis causes the retina...
13 March 2005 - by BioNews 
Three teams of researchers have identified a gene mutation that increases the risk of age-related macular degeneration (AMD), a common cause of blindness in the elderly. The discovery could help identify people who are vulnerable to the condition. Although the causes of AMD are thought to include many genetic and...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.